Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol

Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol

A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BARNSCHEID, LUTZ, GEISSLER. ANJA
Format: Patent
Sprache:spa
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BARNSCHEID, LUTZ
GEISSLER. ANJA
description A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CL2014000361A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CL2014000361A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CL2014000361A13</originalsourceid><addsrcrecordid>eNqNjrFqAzEMhm_JUJq-g6BrkvruSvcQGjp07H4IWxcEtuTaPkgeLO9XJXTq1Eno-_X96KG7HrUkhEAQtPLMHj2rwIxGPS3NAGjBCIUq10bSCBCKpsyJbdObanEi0QqjcwLewkISLA4KeFIx0VoyKwfaAEr7C-ECi4CeOdz7skbG-L1wtNY7SDA4t3POweklaVx3qxljpaff-dg9H9-_Dh9byjpRzfa6UJsOn4PrX80a3_p9P_7v6ge99lud</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol</title><source>esp@cenet</source><creator>BARNSCHEID, LUTZ ; GEISSLER. ANJA</creator><creatorcontrib>BARNSCHEID, LUTZ ; GEISSLER. ANJA</creatorcontrib><description>A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.</description><language>spa</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140620&amp;DB=EPODOC&amp;CC=CL&amp;NR=2014000361A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76418</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140620&amp;DB=EPODOC&amp;CC=CL&amp;NR=2014000361A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BARNSCHEID, LUTZ</creatorcontrib><creatorcontrib>GEISSLER. ANJA</creatorcontrib><title>Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol</title><description>A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjrFqAzEMhm_JUJq-g6BrkvruSvcQGjp07H4IWxcEtuTaPkgeLO9XJXTq1Eno-_X96KG7HrUkhEAQtPLMHj2rwIxGPS3NAGjBCIUq10bSCBCKpsyJbdObanEi0QqjcwLewkISLA4KeFIx0VoyKwfaAEr7C-ECi4CeOdz7skbG-L1wtNY7SDA4t3POweklaVx3qxljpaff-dg9H9-_Dh9byjpRzfa6UJsOn4PrX80a3_p9P_7v6ge99lud</recordid><startdate>20140620</startdate><enddate>20140620</enddate><creator>BARNSCHEID, LUTZ</creator><creator>GEISSLER. ANJA</creator><scope>EVB</scope></search><sort><creationdate>20140620</creationdate><title>Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol</title><author>BARNSCHEID, LUTZ ; GEISSLER. ANJA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CL2014000361A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2014</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BARNSCHEID, LUTZ</creatorcontrib><creatorcontrib>GEISSLER. ANJA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BARNSCHEID, LUTZ</au><au>GEISSLER. ANJA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol</title><date>2014-06-20</date><risdate>2014</risdate><abstract>A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising an opioid agonist, an opioid antagonist, and a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol, wherein in accordance with Ph. Eur. the in vitro release profile of the opioid agonist essentially corresponds to the in vitro release profile of the opioid antagonist, and wherein the opioid agonist and the opioid antagonist are intimately mixed with one another and homogeneously dispersed in the polyalkylene oxide. The pharmaceutical dosage form is useful, for example, to treat pain in a patient in need of such treatment.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language spa
recordid cdi_epo_espacenet_CL2014000361A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Forma de dosificacion farmaceutica oral resistente a rompimiento de al menos 300n comprendiendo agonista opioide, antagonista opioide y un oxido de polialquileno de pm 200.000 g/mol
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A35%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BARNSCHEID,%20LUTZ&rft.date=2014-06-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECL2014000361A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true